Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

2615 results

Sort By:

The Brain Health PRO Online Risk Factor Reduction Study to Prevent Dementia

Study ID: NCT07364019
Start Date: 2026-03-01
End Date: 2028-10-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

700

Intervention / Treatment

Brain Health PRO

Brain Health PRO

Sponsor

University of British Columbia

Source: clinicaltrials.gov

Share:
Add to list

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Study ID: NCT07299019
Start Date: 2026-03
End Date: 2030-07
Study Type

Interventional

Study Phase

Phase3

No. of Participants

990

Intervention / Treatment

Orelabrutinib

Placebo

Sponsor

Zenas BioPharma (USA), LLC

Source: clinicaltrials.gov

Share:
Add to list

Safety and Efficacy of Bone Bioengineering Kit With Stem Cells for Alveolar Cleft Repair

Study ID: NCT07305623
Start Date: 2026-07
End Date: 2027-12
Study Type

Interventional

Study Phase

Phase3

No. of Participants

205

Intervention / Treatment

Bioengineering kit composed of stem cells from deciduous teeth and biomaterial.

iliac crest bone graft surgery

Sponsor

Paraná Institute of Technology

Source: clinicaltrials.gov

Share:
Add to list

Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL

Study ID: NCT06879262
Start Date: 2026-02-15
End Date: 2029-02-28
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

60

Intervention / Treatment

CAR1922T2 T cells（Targeting CD19 and CD22 with CAR-T cells）

Sponsor

Tongji Hospital

Source: clinicaltrials.gov

Share:
Add to list

Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer

Study ID: NCT07369986
Start Date: 2026-03-01
End Date: 2028-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

30

Intervention / Treatment

Iparomlimab and Tuvonralimab (QL1706)

Sponsor

Women's Hospital School Of Medicine Zhejiang University

Source: clinicaltrials.gov

Share:
Add to list

Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)

Study ID: NCT07357103
Start Date: 2026-03
End Date: 2029-09
Study Type

Interventional

Study Phase

Phase4

No. of Participants

416

Intervention / Treatment

Clindamycin + primaquine

Pentamidine

Atovaquone

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Source: clinicaltrials.gov

Share:
Add to list

A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome

Study ID: NCT07285005
Start Date: 2026-02-26
End Date: 2028-02
Study Type

Interventional

Study Phase

Phase3

No. of Participants

150

Intervention / Treatment

KP-001

Placebo

Sponsor

Kaken Pharmaceutical

Source: clinicaltrials.gov

Share:
Add to list

Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus

Study ID: NCT06488469
Start Date: 2026-07-01
End Date: 2026-12-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

50

Intervention / Treatment

Psychological Interventions for children and adolescents

Sponsor

University of Pittsburgh

Source: clinicaltrials.gov

Share:
Add to list

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

Study ID: NCT06982222
Start Date: 2026-03-31
End Date: 2027-02-12
Study Type

Interventional

Study Phase

Phase1

No. of Participants

24

Intervention / Treatment

Biospecimen Collection

Bone Scan

Computed Tomography

Positron Emission Tomography

PSMA PET Scan

Single Photon Emission Computed Tomography

Technetium TC-99m

Tin Sn 117m Pentetate

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases

Study ID: NCT07321847
Start Date: 2026-05
End Date: 2033-12
Study Type

Interventional

Study Phase

Phase3

No. of Participants

717

Intervention / Treatment

1.0% IP-001 for Injection, a 10 mg/mL solution of IP-001 in water

1.0% IP-001 for Injection, a 1 mg/mL solution of IP-001 in water.

Microwave (thermal) tumor ablation

Sponsor

Immunophotonics, Inc.

Source: clinicaltrials.gov

Share:
Add to list